Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can a first disease-modifying osteoarthritis drug make it past the FDA?

Nature reviews. Drug discovery·2026
Same author

Editor's pick: Firefly Bio.

Nature biotechnology·2025
Same author

Editor's Pick: Seaport Therapeutics.

Nature biotechnology·2025
Same author

Probing the proteome.

Nature biotechnology·2025
Same author

How protein-slayer drugs could beat some of the cruellest cancers.

Nature·2025
Same author

First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon.

Nature reviews. Drug discovery·2025
Same journal

Author Correction: Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates.

Nature biotechnology·2026
Same journal

Unlocking the chemical potential of filamentous fungi using prime editing.

Nature biotechnology·2026
Same journal

A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.

Nature biotechnology·2026
Same journal

Prime editing for precise genome engineering and modulation of fungal metabolism.

Nature biotechnology·2026
Same journal

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026
Same journal

A retargeted recombinase for precise insertion of large DNA.

Nature biotechnology·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
09:18

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

Published on: September 7, 2021

Proteostasis therapeutics

Ken Garber

    Nature Biotechnology
    |December 17, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)
    07:22

    The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)

    Published on: January 12, 2024

    Related Experiment Videos

    Last Updated: Jun 17, 2026

    Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
    09:18

    Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans

    Published on: September 7, 2021

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)
    07:22

    The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS)

    Published on: January 12, 2024